Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 5.68 (-0.18%)
Kamada Reports Financial Results for First Quarter of 2019

-- Q1 2019 Proprietary Products Revenues up 67% Year-over-Year

KMDA : 5.68 (-0.18%)
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

KMDA : 5.68 (-0.18%)
LOGC : 16.21 (+9.45%)
CTST : 5.72 (+0.53%)
TAK : 17.71 (+1.61%)
Kamada (KMDA) Stock Moves -1.05%: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.

KMDA : 5.68 (-0.18%)
Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the first quarter and ended March 31, 2019, prior to the open...

KMDA : 5.68 (-0.18%)
Kamada (KMDA) Gains As Market Dips: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.

KMDA : 5.68 (-0.18%)
Kamada (KMDA) Gains As Market Dips: What You Should Know

Kamada (KMDA) closed at $6.13 in the latest trading session, marking a +0.02% move from the prior day.

KMDA : 5.68 (-0.18%)
Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

KMDA : 5.68 (-0.18%)
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

PDLI : 2.96 (-0.67%)
MRUS : 13.14 (-2.60%)
KMDA : 5.68 (-0.18%)
TAK : 17.71 (+1.61%)
Kamada announces FDA acceptance of Inhaled AAT program path forward

Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food and Drug Administration (FDA or the Agency) stating that the Company...

KMDA : 5.68 (-0.18%)
5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.

FBP : 10.12 (+1.10%)
BBSI : 75.19 (-0.29%)
ANIP : 68.47 (+0.06%)
KMDA : 5.68 (-0.18%)
WD : 52.01 (+0.83%)
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

SKYW : 59.95 (+1.22%)
ANIP : 68.47 (+0.06%)
KMDA : 5.68 (-0.18%)
SP : 31.53 (-0.66%)
HRI : 36.89 (-0.54%)
Acorda to Gain From Inbrija Sales and Neurological Pipeline

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

MYL : 18.98 (-0.99%)
PDLI : 2.96 (-0.67%)
ACOR : 10.16 (-1.17%)
KMDA : 5.68 (-0.18%)
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

BDSI : 4.39 (-0.90%)
ANIP : 68.47 (+0.06%)
TEVA : 10.87 (-1.54%)
KMDA : 5.68 (-0.18%)
Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Kamada (KMDA) closed at $5.95, marking a -1.16% move from the previous day.

KMDA : 5.68 (-0.18%)
Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.

SKYW : 59.95 (+1.22%)
ANIP : 68.47 (+0.06%)
SNX : 94.45 (+1.30%)
KMDA : 5.68 (-0.18%)
SP : 31.53 (-0.66%)
HRI : 36.89 (-0.54%)
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

AZN : 39.02 (+0.93%)
ANIP : 68.47 (+0.06%)
KMDA : 5.68 (-0.18%)
PHAS : 10.52 (+6.59%)
Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

EBS : 43.27 (-0.32%)
KMDA : 5.68 (-0.18%)
GSK : 40.18 (+0.48%)
SNY : 42.28 (+0.40%)
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

PDLI : 2.96 (-0.67%)
AZN : 39.02 (+0.93%)
INO : 3.26 (+0.31%)
KMDA : 5.68 (-0.18%)
Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

KMDA : 5.68 (-0.18%)

Van Meerten Stock Picks

NextEra Energy - Large Cap Pick
The Large Cap Pick of the Day is electric utility company NextEra Energy(NEE).
NEE -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar